This story reports on a investigational drug, flibanserin, that is being developed to treat what is a controversial diagnosis called "hypoactive sexual desire" in women. The popular press has dubbed this drug "Female Viagra" despite that fact that it has few similarities to drugs that treat erectile dysfunction. Preliminary research examining the drug’s efficacy in treating sexual distress and/or low sexual desire were presented at the May 2010 annual clinical meeting of the American College of Obstetricians and Gynecologists (ACOG). To place the story in context, previous reports from the manufacturer claimed that flibanserin resulted in "clinically significant" improvement in the number of sexually satisfying events reported by women taking the drug vs. those taking placebo, an absolute difference of 0.7 events per month. The story was detailed and did a good job of presenting information in absolute terms so that the reader could clearly see that reported benefits were small and of unknown clinical significance.
Good reminders that this is a controversial diagnosis and that "some experts see it as the medicalization of what is for many women a relationship issue."
Cost data for flibanserin is not provided. Some projection of cost should be available for any drug this far along in Phase III trials – and for which the company has already begun marketing campaigns. If not from the company, then from stock analysts.
The story properly quantifies the reported benefits in absolute terms which allows the reader to see that they are small. (Results are described in Quality of Evidence comments.) In an interview a study researcher conceded that the absolute number of women reporting benefit was not large.
The story provided statistics on common side effects including daytime sleepiness, dizziness, fatigue, anxiety, dry mouth, nausea and insomnia. These side effects resulted in 15% of those taking flibanserin vs 7% taking placebo withdrawing from the study.
The story does a good job of presenting and evaluating the available evidence. Results are presented in absolute terms, for example that just under one third of women taking flibanserin reported improvement in sexual distress/desire compared to approximately one fifth of women taking placebo. In contrast, these results were presented in relative terms by the manufacturer.
Except for the headline, " ‘Female Viagra’ May Treat Low Sexual Desire", this story avoids disease mongering and notes that "hypoactive sexual desire disorder" in women is a controversial diagnosis. The text clarifies that while the popular press is dubbing flibanserin as the "female Viagra", it is not similar to Viagra or other drugs to treat erectile dysfunction.
Conflicts of interest are disclosed. The story noted that the study researcher interviewed is a paid consultant for the drug manufacturer. An alternative point of view is provided by two independent experts, a psychologist and a sex-therapist. The independent sources comment on the role that personal relationships play in sexual desire and experience which was not addressed or acknowledged by the researchers.
The story indicates that an alternative drug called the Intrinsa testosterone patch is available in Europe, but not in the U.S. The story also notes a difference between these dugs; Intrinsa is a hormonal treatment compared to flibanserin which is a non-hormonal.
The story indirectly informs that reader that flibanserin is not available by noting that it is in phase III clinical trials and that the manufacturer is seeking FDA approval (despite early direct to consumer marketing campaigns).
The story makes it fairly clear that this is a new treatment – also for a new and controversial diagnosis.
The story was apparently based on research presented in abstract form at the annual clinical meeting of the American College of Gynecologists and Obstetricians, although this information has not been published in independently, peer-referred scientific journals.
There is no direct evidence that it relied largely on a news release. In fact, the use of interviews with independent experts makes it clear that independent reporting took place.
Systematic, Criteria-Driven
We’ve written about the hype of liquid biopsies for years (see link in comment below). And now this…. https://www.statnews.com/2022/01/12/medicare-shouldnt-cover-liquid-biopsies-early-cancer-detection/
Case counts still matter. “(There) are stories that may not be told adequately if only hospitalizations and deaths are emphasized.” @garyschwitzer interviewed by @dbauder of @AP. https://apnews.com/article/omicron-changing-news-outlets-covid-data-da9272f7c4c8a109c3bfb56bed9e9c76
My friend Gary @garyschwitzer wrote to his city council representative in a Minnesota town about a Viva Las Vegas event scheduled for January.
The response he got seems to perfectly capture where we are now.
https://www.healthnewsreview.org/2021/12/2021-ends-with-covid-craziness-in-sports-and-politics/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like